EUVIMEDEUVIMED entdecken
Open Access

Nephrotic syndrome in mice elevates FGF23 levels and leads to cardiac hypertrophy in the absence of hyperphosphatemia

Abul Fajol, Qing Li, S Madison Thomas, Alexis Sloan, Lihao He, Min Xie, Kylie Heitman, Dominik Kentrup, Christopher Yanucil, Alexander Grabner, Sandra Merscher, Alessia Fornoni und 2 weitere

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfaf272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Abul Fajol und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Mineral Metabolism, Division of Nephrology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, …. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Nephrotic Syndrome, Cardiomegaly, Hyperphosphatemia. Die Arbeit nennt 141 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis Patients with nephrotic syndrome develop albuminuria, hyperlipidemia, and heart failure, but the pathomechanisms underlying this interconnection are unclear. We previously found that fibroblast growth factor 23 (FGF23) promotes cardiac hypertrophy in animal models of chronic kidney disease (CKD). Since patients with nephrotic syndrome have elevated FGF23, we hypothesized that FGF23 also contributes to heart damage in nephrotic syndrome.

Methods

We previously developed a mouse model with the inducible and podocyte-specific overexpression of a constitutively active NFATc1 mutant variant (NFATc1nuc), which within 1 week develops a nephrotic syndrome-like phenotype. Here, we conducted serological analyses of phosphate and lipid metabolism, and we studied the cardiac phenotype after 1 week and 3 months of albuminuria.

Results

After 1 week, mice presented with albuminuria, hyperlipidemia, and elevated serum FGF23 levels, as well as reductions in cardiac function and cardiac hypertrophy on a cellular level without significant increases in cardiac mass or fibrosis. Under physiologic conditions and in CKD, elevations in systemic phosphate levels, also called hyperphosphatemia, induce FGF23 production in the bone. However, in NFATc1nuc mice we could detect neither increases in serum phosphate levels nor in FGF23 expression in the bone. Instead, nephrotic mice had FGF23 elevations in the heart, and our in vitro studies showed that free fatty acids induced FGF23 expression in cardiac myocytes resulting in hypertrophy. We also found that mice with prolonged NFATc1nuc expression transition into a CKD-like phenotype with hyperphosphatemia and further FGF23 elevations, as well as cardiac hypertrophy and fibrosis and a reduced lifespan.

Conclusion

Our study suggests that NFATc1nuc mice serve as a model of nephrotic syndrome that progresses to CKD with pathologic cardiac remodeling. Our findings indicate that hyperlipidemia might contribute to heart failure in nephrotic syndrome by inducing FGF23 expression in the heart, which then drives cardiac hypertrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth FactorsNephrotic SyndromeCardiomegalyHyperphosphatemiaAnimalsFibroblast Growth Factor-23MiceDisease Models, AnimalMaleMice, Inbred C57BL

Stichwörter der Autor:innen

FGF23cardiac hypertrophyfree fatty acidsnephrotic syndromephosphate

Substanzen

Fibroblast Growth Factor-23Fibroblast Growth FactorsFgf23 protein, mouseFGF23 protein, human

Autor:innen und Institutionen

  • Section of Mineral Metabolism, Division of Nephrology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
  • Katz Family Division of Nephrology and Hypertension, Department of Medicine, and Peggy and Harold Katz Family Drug Discovery Center, and University of Miami Miller School of Medicine, Miami, FL, USA.
  • Division of Cardiovascular Disease, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
  • Division of Nephrology, Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Christian Faul

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NIH HHS
  • American Heart Association
  • Miami Clinical Translational Science Institute
  • NIH

Zitieren

APA

Fajol, A., Li, Q., Thomas, S. M., Sloan, A., He, L., Xie, M., Heitman, K., Kentrup, D., Yanucil, C., Grabner, A., Merscher, S., Fornoni, A., Gutierrez, O. M., & Faul, C. (2025). Nephrotic syndrome in mice elevates FGF23 levels and leads to cardiac hypertrophy in the absence of hyperphosphatemia. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf272

Vancouver

Fajol A, Li Q, Thomas SM, Sloan A, He L, Xie M, et al. Nephrotic syndrome in mice elevates FGF23 levels and leads to cardiac hypertrophy in the absence of hyperphosphatemia. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf272

BibTeX
@article{Fajol2025,
  author = {Fajol, Abul and Li, Qing and Thomas, S Madison and Sloan, Alexis and He, Lihao and Xie, Min and Heitman, Kylie and Kentrup, Dominik and Yanucil, Christopher and Grabner, Alexander and Merscher, Sandra and Fornoni, Alessia and Gutierrez, Orlando M and Faul, Christian},
  title = {Nephrotic syndrome in mice elevates FGF23 levels and leads to cardiac hypertrophy in the absence of hyperphosphatemia},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfaf272}
}
Kostenlos starten →